Skip to content
Axe Capital logo Axe Capital Trading News

Redwire Climbs 14.3% in Six Months: Is the Stock Still a Buy?

2026-09-04 13:31 Na Zacks Investment Research Mixed Axe Cap view: Selective EquitiesM&A RDWHIIRTX

Axe Cap view

Redwire Up 14% But Premium Valuation Counsels Caution

Redwire’s strong backlog and niche tech gains offset by persistent losses and high valuation.

Redwire’s 14.3% rise over six months bucks the aerospace-defense sector’s slide, thanks to fresh Defense Tech capabilities and a $542 million backlog. That said, it still operates at a loss, burning $117 million in H1 2026, and carries a pricey 4.9x forward sales multiple, double the industry average. This premium reflects optimism on its phased array antenna tech and potential space communications contracts but also heightens risk if expected deals falter. For South African investors, direct exposure is limited, yet the stock’s performance parallels the rand’s vulnerability to global risk off moves. JSE fundamentals like Sasol’s commodity-driven outlook or MTN’s more stable cash flow offer clearer value. If you’re watching the aerospace sector via USD/ZAR swings, exercise patience. If Redwire’s tech breakthroughs take hold, gains could surprise—but at this price, it’s safer to wait for a pullback. Bear in mind, any setbacks in contract execution could reverse recent gains quickly;. this is just our opinion and not financial advice

How I would invest

Avoid buying Redwire at current prices; wait for a significant correction before considering exposure. Focus instead on local names with clearer earning power and linkages to currency softness or strength.

What I would watch
  • USD/ZAR
  • Sasol
What could go wrong
  • Contract execution failure
  • Extended losses draining cash flow
How strongly I feel

5/10

Redwire Corporation (RDW) has gained 14.3% over six months, outperforming its industry decline of 15.1%, driven by Defense Tech expansion following the Edge Autonomy acquisition and rising backlog to $542.1M. However, the company faces continued losses ($117.5M in H1 2026), elevated R&D costs, and contract execution risks. Trading at a premium valuation (4.89X forward P/S vs. industry 2.36X), the stock is rated a Hold with new investors advised to wait for better entry points.

Our take is based on reporting first published by Zacks Investment Research.

Read the original story